We are here for you.

Your Contacts


Prof. Dr. Peter Bramlage

Prof. Dr. Peter Bramlage, FESC, FACC

Managing Director and Shareholder of the GmbH
Partnerschaftsgesellschaft Dr. Bramlage & Dr. Hankowitz

Dr. Bramlage began his medical training at the Justus-Liebig University in Gießen (Germany). His studies then took him to the Universities of Vienna (Austria) and Columbia (Missouri, USA). On returning from the USA, he completed his PhD at the Max Planck Institute for Physiological and Clinical Research, Bad Nauheim. From 1998 he worked at the Charite University Hospital, Berlin, in the Medical Clinic and the Outpatient Clinic for Cardiology and Angiology. In 2002 he switched his Focus into Clinical Pharmacology and Epidemiology, and since then, has held a number of positions at Sanofi Aventis and the Institute for Clinical Pharmacology at the TU Dresden.

During his time in Bad Nauheim, Dr Bramlage investigated the functional adaptation of cardiomyocytes to a variety of diseases that involve myocardial ischaemia. Since then, he has dealt with many topics in the fields of cardiovascular pharmacology and epidemiology. He has also recently been involved in major epidemiological studies concerning aortic stenosis, arterial hypertension, diabetes, and the metabolic syndrome, and in a series of clinical studies on the treatment of cardiovascular disease.

Dr Bramlage has published over 400 articles in peer-reviewed journals and is an active member of the League for the Fight Against High Blood Pressure and the German Society of Cardiology. He is also a Fellow of the European Society of Cardiology (FESC) and of the American College of Cardiology (FACC). He is a member of the Editorial Board of Expert Opinion on Pharmacotherapy.


Dr. Johannes Hankowitz

Dr. Johannes Hankowitz

Partnerschaftsgesellschaft Dr. Bramlage & Dr. Hankowitz

Dr. Hankowitz studied pharmacy and philosophy with a focus on ethics, scientific theory, and structural research at the University of Münster and the Max Planck Institute for Biochemistry in Martinsried, near Munich, Germany. His doctoral dissertation, completed at the Institute for Clinical Chemistry, was on the topic of the effects of drugs on signal transduction in atherogenic processes. He subsequently worked as a research associate at the Regensburg University Hospital, in the Institute for Clinical Chemistry, focusing on immunology and oncology.

During his work, Dr Hankowitz received a Master’s degree in European Studies (M.E.S.) from the RWTH Aachen University, with a legal thesis on pharmacovigilance. He then moved to Sanofi Winthrop, working in the field of antithrombotics. He later became Medical Director of Sanofi-Synthelabo in the areas of thrombosis, cardiology, and the CNS, and Director of Medicine and Marketing for thrombosis and cardiology. Following this, he was the Head of Medicine and Pharmacy at Winthrop Arzneimittel GmbH, and was a company Director. Dr Hankowitz has experience in all aspects relevant to the AMG (German Medicinal Products Act), including data management, risk categorisation, and controlled drugs; being a Qualified Person; and marketing management.

Mr. Hankowitz is owner and editor of AMNOG-monitor – an interactive analysis tool for evaluation of all G-BA resolutions according to §35a SGB V. He is an expert of early benefit assessment in Germany including phase III clinical programme, Joint Scientific Advise (BfArM & G-BA), strategic consulting & compilation of benefit dossiers and price negotiations.